64Cu-FBP8
Cardiac Amyloidosis
Brigham and Women's HospitalPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Cardiac Amyloidosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Florbetaben Lantheus Germany GmbH | Phase 3 | BBB |
EVUZAMITIDE Lorena Saelices | Phase 3 | BB |
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE Medical College of Wisconsin | Phase 4 | BB |
[68ga]cbp8 Brigham and Women's Hospital | Phase 3 | B |
DEXAMETHASONE Seoul National University Hospital | Phase 2 | CCC |
Thalidomide Seoul National University Hospital | Phase 2 | CCC |
NOS University of Pennsylvania | Early Phase 1 | C |
Flutemetamol University Hospital, Toulouse | Early Phase 1 | C |
Same molecule, other indications
64Cu-FBP8 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →